Sara Elizabeth Townsley

Array ( [id] => 19379241 [patent_doc_number] => 20240269111 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING OCULAR NEOVASCULAR DISEASE [patent_app_type] => utility [patent_app_number] => 18/561103 [patent_app_country] => US [patent_app_date] => 2022-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30304 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -197 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18561103 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19297540 [patent_doc_number] => 20240226105 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-11 [patent_title] => TETRODOTOXIN LIQUID FORMULATIONS [patent_app_type] => utility [patent_app_number] => 18/556683 [patent_app_country] => US [patent_app_date] => 2022-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15791 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18556683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19343545 [patent_doc_number] => 20240252508 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => Novel glucose uptake inhibitors for use in the treatment of cancer [patent_app_type] => utility [patent_app_number] => 18/553576 [patent_app_country] => US [patent_app_date] => 2022-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25536 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18553576 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19170799 [patent_doc_number] => 20240156773 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => METHOD FOR INCREASING BLOOD DECANOIC ACID CONCENTRATION, BLOOD-DECANOIC-ACID-CONCENTRATION-INCREASING AGENT, PHARMACEUTICAL COMPOSITION, AND FOOD COMPOSITION [patent_app_type] => utility [patent_app_number] => 18/552283 [patent_app_country] => US [patent_app_date] => 2022-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5811 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18552283 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20206226 [patent_doc_number] => 20250275946 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-04 [patent_title] => COMBINATION THERAPY FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 18/269854 [patent_app_country] => US [patent_app_date] => 2022-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14447 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18269854 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19430850 [patent_doc_number] => 20240299348 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/260670 [patent_app_country] => US [patent_app_date] => 2022-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21720 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18260670 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20218545 [patent_doc_number] => 20250281476 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-11 [patent_title] => EFINACONAZOLE ORAL COMPOSITION [patent_app_type] => utility [patent_app_number] => 18/259509 [patent_app_country] => US [patent_app_date] => 2021-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2076 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18259509 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879008 [patent_doc_number] => 20240002377 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => PYRROLOPYRIDINE COMPOUND AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/039144 [patent_app_country] => US [patent_app_date] => 2021-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7032 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18039144 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18901299 [patent_doc_number] => 20240016784 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => Y BOX BINDING PROTEIN 1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/255827 [patent_app_country] => US [patent_app_date] => 2021-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29912 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 256 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18255827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19232078 [patent_doc_number] => 20240189269 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => PHARMACEUTICAL COMPOSITION FOR SUPPRESSING TMPRSS2 EXPRESSION [patent_app_type] => utility [patent_app_number] => 18/552289 [patent_app_country] => US [patent_app_date] => 2021-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4539 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18552289 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18844452 [patent_doc_number] => 20230406856 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3, 4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/253252 [patent_app_country] => US [patent_app_date] => 2021-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14290 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18253252 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20049862 [patent_doc_number] => 20250188084 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-06-12 [patent_title] => COMPOUNDS AND METHODS FOR MODULATING CDK9 ACTIVITY [patent_app_type] => utility [patent_app_number] => 18/034634 [patent_app_country] => US [patent_app_date] => 2021-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15452 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18034634 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18817425 [patent_doc_number] => 20230391765 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL [patent_app_type] => utility [patent_app_number] => 18/032758 [patent_app_country] => US [patent_app_date] => 2021-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 86554 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18032758 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18806837 [patent_doc_number] => 20230381170 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => METHOD FOR TREATING ALS/FTD THROUGH DEGRADATION OF RNA REPEAT EXPANSION [patent_app_type] => utility [patent_app_number] => 18/032648 [patent_app_country] => US [patent_app_date] => 2021-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28686 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18032648 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19387788 [patent_doc_number] => 20240277658 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME [patent_app_type] => utility [patent_app_number] => 18/030875 [patent_app_country] => US [patent_app_date] => 2021-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42077 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18030875 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18939584 [patent_doc_number] => 20240034723 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/031077 [patent_app_country] => US [patent_app_date] => 2021-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27222 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18031077 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18895167 [patent_doc_number] => 20240010652 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES [patent_app_type] => utility [patent_app_number] => 18/031688 [patent_app_country] => US [patent_app_date] => 2021-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20994 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18031688 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18786042 [patent_doc_number] => 20230373998 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => SOLID STATE FORMS OF LORECIVIVINT [patent_app_type] => utility [patent_app_number] => 18/030785 [patent_app_country] => US [patent_app_date] => 2021-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7430 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18030785 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18842584 [patent_doc_number] => 20230404988 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => PROSTAGLANDIN RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF A CORONAVIRUS INFECTION SUCH AS COVID-19 [patent_app_type] => utility [patent_app_number] => 18/248129 [patent_app_country] => US [patent_app_date] => 2021-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15064 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18248129 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18860145 [patent_doc_number] => 20230414579 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => PHARMACEUTICALS FOR COVID19 TREATMENT [patent_app_type] => utility [patent_app_number] => 18/248278 [patent_app_country] => US [patent_app_date] => 2021-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4793 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18248278 [rel_patent_id] =>[rel_patent_doc_number] =>)